ABBV Will Fly Once This HappensABBV Will Fly Once This Happens
NYSE:ABBV is one of those incredible companies, not just because of what they do, but how they do it. They have consistently ranked among the best for employee well-being while successfully bringing to market some of the most patent-protected biotech drugs, such a
AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1
No trades
5.26 T ARS
76.17 T ARS
About AbbVie Inc.
Sector
Industry
CEO
Robert A. Michael
Website
Headquarters
North Chicago
Founded
2011
IPO date
Jan 2, 2013
Identifiers
2
ISIN ARBCOM4603M9
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Related stocks
AbbVie Inside a Falling ChannelAbbVie is currently trading inside a descending channel, following a strong impulsive bullish move. This structure suggests a controlled correction rather than a trend reversal, at least for now.
Price is oscillating around the midline of the channel and near the moving average, indicating short-te
AbbVie in Descending ChannelThe chart shows AbbVie Inc. (ABBV) on the daily timeframe.
After a strong impulsive rally (black trendline leg), price entered a descending parallel channel, indicating a corrective phase rather than a confirmed trend reversal — at least for now.
Current price: ~231
Price is testing the upper boun
AbbVie tests $225 as buyers step in ahead of catalysts:Current Price: 223.01 (Analysis was generated on Monday Morning)
Direction: LONG
Confidence level: 58%(Limited volume of trader commentary but consistent focus on $219 support and price holding above key moving averages supports a cautious long bias.)
Targets
Target 1: 225.00
Target 2: 226.00
St
ABBV Stock Analysis [1D TF]
Fundamental/Market Context
AbbVie (ABBV) continues to benefit from a diversified portfolio led by strong immunology and oncology franchises. Recent earnings have generally topped expectations, supporting confidence in cash flow and dividend sustainability, while pipeline catalysts provide medium-t
ABBVIE topped and looks for a 2026 Bear Cycle.AbbVie Inc. (ABBV) has been trading within a Channel Up for almost the past 4 years (since the April 04 2022 High) and seems to have topped on its latest September 29 2025 Higher High as it turned sideways since.
On that September top, the 1W RSI also got rejected from overbought territory, which i
Healthy Pullback or Trend Reversal?Bullish Scenario (Primary)
• Strong uptrend structure
• Sharp impulse move followed by bullish consolidation (triangle)
• Pullback is constructive, not trend-breaking
• Price holding above 50-day SMA
📍 Entry Zone:
• $225 – $230
🛑 Stop Loss:
• $212
• Daily close below invalidates bullish se
ABBV Undervalued Pharma? Strong Dividend Play?ABBV – Financial Performance & SWOT Analysis
ABBV Undervalued Pharma? Strong Dividend Play?
(1/9)
Good evening, folks! ABBV is climbing 🚀, at $ 230.69 up 33.40% YTD per October 10, 2025. Q2 revenue shakes up this pharma play , let’s dive in! 📊🔥 Tag a friend who needs this investing hack!
(2/9)
ABBV at a Breakout Point: Golden Opportunity or Bull Trap?🔎 Short-Term Outlook (weeks to a few months)
Current Situation:
The stock is testing the strong resistance zone at $222–225, which has acted as a ceiling multiple times in the past.
Bullish Scenario:
A confirmed breakout and consolidation above $225 would validate bullish momentum.
🎯 Target 1: $235
ABBV AUG 2025ABBV is approaching a strong resistance zone after heavy selling volume near 210–215. The stock recently broke higher, but price is testing supply after a fast rally.
Institutional absorption was seen at 190 and 195, with 205 now acting as immediate support.
Upside target: 212–215 if buyers absorb
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.









